WE CLAIM:

1. An anti-C5 antibody, wherein the antibody binds to C5 and inhibits complement dependent hemolysis, but does not block C5a formation.

2. The antibody of claim 1, wherein the antibody blocks C5 binding to human Complement Component 6 and/or 7.

3. The antibody of claim 1, wherein the antibody inhibits formation of membrane attack complex (MAC).

4. The antibody of claim 1, wherein antibody comprising a first amino acid sequence and a second amino acid sequence comprising:

(a) the first sequence comprising;

(i) a CDR1 selected from the group consisting of SEQ ID NOs:13, 18, 23, 28, 33, and 38;

(ii) a CDR2 selected from the group consisting of amino acids sequence GTS, SGS, RTS, YTS and WAS; and

(iii) a CDR3 selected from the group consisting of SEQ ID NOs:14, 19, 24, 29, 34, and 39; and

(b) the second sequence comprising

(i) a CDR1 selected from the group consisting of SEQ ID NOs:15, 20, 25, 30, 35, and 40;

(ii) a CDR2 selected from the group consisting of SEQ ID NOs:16, 21, 26, 31, 36, and 41; and

(iii) a CDR3 selected from the group consisting of SEQ ID NOs:17, 22, 27, 32, 37, and 42.

5. The antibody of claim 4, further comprising a heavy chain and a light chain wherein

the light chain comprises an amino acid sequence at least 80% identical to a sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, and 11; and

the heavy chain comprises an amino acid sequence at least 80% identical to a sequence selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, and 12.

6. The antibody of claim 1, wherein the antibody comprises a heavy chain and a light chain variable domain selected from the heavy and light chain variable sequences: SEQ ID NO:1/ SEQ ID NO:2; SEQ ID NO:3/ SEQ ID NO:4; SEQ ID NO:5/ SEQ ID NO:6; SEQ ID NO:7/ SEQ ID NO:8; SEQ ID NO:9/ SEQ ID NO:10; and SEQ ID NO:11/ SEQ ID NO:12.

7. The antibody of claim 1, wherein the antibody is a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof.

8. The antibody of claim 7, wherein the antibody is an antibody fragment and the antibody fragment is a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment, a Fv fragment, a diabody, or a single chain antibody molecule.

9. The antibody of claim 7, wherein said antibody is of the IgG1-, IgG2- IgG3- or IgG4-type.

10. The antibody of claim 9, wherein the antibody is of an IgG1-type.

11. The antibody of claim 1, wherein the antibody is coupled to a labelling group.

12. The antibody of claim 12, wherein the labelling group is an optical label, radioisotope, radionuclide, an enzymatic group, and a biotinyl group.

13. A process for preparing an isolated antibody according to any one of claims 1, comprising preparing said antibody from a host cell that secretes said antibody.

14. A nucleic acid molecule encoding an isolated antibody according to any one of claims 1.

15. The nucleic acid molecule according to claim 14, wherein the nucleic acid molecule is operably linked to a control sequence.

16. A pharmaceutical composition comprising at least one antibody according to any one of claims 1 and pharmaceutically acceptable carrier.

17. The pharmaceutical composition of claim 16, further comprising an additional active agent.

18. A method for treating or preventing an indication in a patient in need of treatment or prevention;

comprising administering to said patient an effective amount of the antibody of claim 1; and thereby treating or preventing the indication.

19. The method of claim 18, wherein the condition is an ocular condition.

20. The method of claim 19, wherein the condition is age-related macular degeneration.